Disease · MONDO_0015798

inflammatory myofibroblastic tumor

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. inflammatory myofibroblastic tumor. Diseases, record MONDO_0015798. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0015798

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: inflammatory myofibroblastic tumor; Open Targets
Open Targets ID: MONDO_0015798; Open Targets
Other names: IMT, inflammatory fibrosarcoma, inflammatory myofibroblastic neoplasm, inflammatory pseudotumor; Open Targets
Disease Ontology: DOID:0050905; Disease Ontology
MeSH: D006104; MeSH
NCI Thesaurus: C6481; NCI Thesaurus
Orphanet: ORPHA:178342; Orphanet
Highest stage of its drugs: Phase 2/3, for 1 of its 3 drugs, from ClinicalTrials.gov; Open Targets

Drugs3

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CRIZOTINIB	CHEMBL601719	Small molecule	Phase 2/3	ClinicalTrials.gov	2	2	2	Drugs and targets
BRIGATINIB	CHEMBL3545311	Small molecule	Phase 1/2	ClinicalTrials.gov	2	2	2	Drugs and targets
CERITINIB	CHEMBL2403108	Small molecule	Phase 1	ClinicalTrials.gov	2	2	2	Drugs and targets

Targets7

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ALK	ALK tyrosine kinase receptor	3	ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor; NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) inhibitor	Phase 2/3	https://conductscience.org/library/genes/238	Drugs and targets
EML4	EML4-ALK	2	EML4-ALK inhibitor	Phase 2/3	https://conductscience.org/library/genes/27436	Drugs and targets
NPM1	NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor)	2	NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) inhibitor	Phase 2/3	https://conductscience.org/library/genes/4869	Drugs and targets
EGFR	Epidermal growth factor receptor	1	Epidermal growth factor receptor erbB1 inhibitor	Phase 1/2	https://conductscience.org/library/genes/1956	Drugs and targets
MET	Hepatocyte growth factor receptor	1	Hepatocyte growth factor receptor inhibitor	Phase 2/3	https://conductscience.org/library/genes/4233	Drugs and targets
MST1R	Macrophage-stimulating protein receptor	1	Macrophage-stimulating protein receptor inhibitor	Phase 2/3	https://conductscience.org/library/genes/4486	Drugs and targets
ROS1	Proto-oncogene tyrosine-protein kinase ROS	1	Proto-oncogene tyrosine-protein kinase ROS inhibitor	Phase 2/3	https://conductscience.org/library/genes/6098	Drugs and targets

Trials6

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01742286	Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)	Phase 1	83	2020-06-09	ALK-activated Tumors	CERITINIB	Its record names the disease	ClinicalTrials.gov
NCT02034981	Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1	Phase 2	246		Hematologic Cancers, Solid Tumors, Metastatic Cancer	CRIZOTINIB	Its record names the disease	ClinicalTrials.gov
NCT04925609	Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors	Phase 1/2	65		Anaplastic Large Cell Lymphoma, ALK-Positive, Inflammatory Myofibroblastic Tumor, Other Solid Tumor	BRIGATINIB	Its record names the disease	ClinicalTrials.gov
NCT03874273	Study of Crizotinib in Children and Adolescents With Myofibroblastic Tumors	Phase 2/3	25		Inflammatory Myofibroblastic Tumor	CRIZOTINIB	Its record names the disease	ClinicalTrials.gov
NCT01634763	Study of Safety and Preliminary Efficacy for LDK378 in Japanese Patients With Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)	Phase 1	22		Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)	CERITINIB	Its record names the disease	ClinicalTrials.gov
NCT04260009	Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors	Phase 1/2	0		Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors, Solid Tumors	BRIGATINIB	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials7

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
37549532	DERIVED	1	PubMed
34780709	DERIVED	1	PubMed
33847874	DERIVED	1	PubMed
31584608	DERIVED	1	PubMed
30697903	DERIVED	1	PubMed
27565932	DERIVED	1	PubMed
26020125	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0015798

GET https://conductscience.org/api/diseases/v1/MONDO_0015798/drugs

API reference For AI assistants